Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

By sjmartinez • March 4, 2023

Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Feb 28:S0140-6736(23)00350-1. doi: 10.1016/S0140-6736(23)00350-1. Epub ahead of print. PMID: 36868261.

Tags: Allergy & Immunology, Publications

Nicolau syndrome: A case of ischemic necrosis after subcutaneous immunotherapy

Kim J, Kaddis T, Boyle S, Gupta S, Wang V, Yusin J. Nicolau syndrome: A case of ischemic necrosis after subcutaneous immunotherapy. J Allergy Clin Immunol[...]

From Mild to Mayhem: A Life-Threatening Exacerbation of Mild Asthma

Brown K, Anderson L. From Mild to Mayhem: A Life-Threatening Exacerbation of Mild Asthma. Cureus. 2024 Sep 30;16(9):e70558. doi: 10.7759/cureus.70558. PMID: 39479137; PMCID: PMC11524714.

Psychosocial issues and quality of life associated with food allergy

Kachru R. Psychosocial issues and quality of life associated with food allergy. J Food Allergy. 2024 Jul 8;2(1):95-98. doi: 10.2500/jfa.2020.2.200025. PMID: 39022158; PMCID: PMC11250222.